Russian paratroopers to take part in Interaction drills in September 2016
Media report shelling of Donetsk outskirts
Kremlin: Early to speak about progress on creating anti-terrorism coalition
Kremlin comments on Erdogan's challenge to reveal evidence of Turkey's purchases of IS oil
Problem of power supply to Crimea will be fundamentally solved in nearest future — PM
Ukraine has not responded to Russia’s proposal on $3 bln debt restructuring yet — ministerBusiness & Economy December 01, 15:47
Some 1.6 mln foreign nationals banned from entering RussiaSociety & Culture December 01, 15:34
Problem of power supply to Crimea will be fundamentally solved in nearest future — PMBusiness & Economy December 01, 15:24
EU migration crisis may affect Russia in future — officialRussian Politics & Diplomacy December 01, 14:57
Russian lawmaker: NATO support for Ankara over Su-24 incident suggests joint provocationRussian Politics & Diplomacy December 01, 14:23
Russian paratroopers to take part in Interaction drills in September 2016Military & Defense December 01, 14:10
Chinese yuan in top 5 most popular currencies in RussiaBusiness & Economy December 01, 14:01
Russia will build 392 buildings for military garrisons in Kuril Islands — defense ministerMilitary & Defense December 01, 13:45
Kremlin: Early to speak about progress on creating anti-terrorism coalitionRussian Politics & Diplomacy December 01, 13:27
KHIMKI, September 6. (ITAR-TASS) – Russian scientists are currently working on the first ever vaccine which could help quit smoking; it may be available in pharmacies in as early as five years. Dmitry Ovchinnikov, Deputy Director General of the company developing the drug, Selecta RUS confirmed: “We’re currently going through the second phase of clinical trials.”
Selecta RUS is a subsidiary of an American innovation company which opened the Khimki branch in 2012. Ovchinnikov said that development of the ‘anti-tobacco’ and other vaccines was moved from the U.S. to Russia, as “experts of required qualification work here.” Favorable financing conditions were also a factor: for instance, the vaccine project has received a grant from Russia’s Ministry of Industry and Trade.
The scientists noted that “existing methods of curing tobacco addiction are ineffective,” adding that the new vaccine will be a breakthrough. The drug makes recipient’s body start producing antibodies which block nicotine before it reaches the brain.
Khimki lab scientists are working on a molecular “nano-container,” which can precisely deliver vaccine components in cells which are responsible for launching immune reaction. Produced anti-bodies bind nicotine contained in blood; the resulting complex becomes too large to bypass the blood–brain barrier, which restrict diffusion of dangerous microscopic objects, such as bacteria and harmful molecules. As a result, nicotine cannot access the brain’s “pleasure center” – thus smoking ceases to bring the feeling of euphoria and satisfaction. The chain of pathological tobacco addiction is thus broken.
Ovchinnikov added that Selecta RUS scientists are also working on other vaccines against other afflictions such as melanoma, type 1 diabetes and hepatitis B.
“Operation of this laboratory is a vivid example of technology transfer to Russia,” said Sergei Filippov, representative of Rusnano. He added that Rusnano owns 12% of SelectaBiosciences, the American company which owns Selecta RUS.